113 search results for: symposium
Mucus Plugging as a Potential Target in Asthma Management
Join Dr. Celeste Porsbjerg as she explores the mechanisms underlying mucus plugging development as mucociliary clearance. She explains how type 2 cytokines—particularly IL-13—impair this clearance mechanism, leading to mucus plugging, and worsened asthma outcomes.
UEGW 2024 | Latest Clinical Evidence for Biologics in EoE
Prof. Salvatore Oliva discusses the latest clinical data for EoE that included patients from childhood to adulthood.
UEGW 2024 | WHAT Can Be Used to Monitor Treatment Response in EoE and WHEN?
Dr. Milli Gupta emphasizes the need to regularly monitor multiple disease domains when assessing treatment response, not just EoE symptoms.
UEGW 2024 | WHY Is Long-Term Management of EoE Important?
Prof. Salvatore Oliva discusses the impact of chronic type 2 inflammation on EoE progression, highlighting the need for long-term management.
A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in PN and CSU
Join Drs. Elmariah, Kim, and Metz as they explore the latest research on neuro-immune mechanisms driving chronic itch and inflammation in PN and CSU.
UEGW 2024 | Something to Chew On: Exploring Biologics in EoE Management
Prof. Salvatore Oliva and Dr. Milli Gupta discuss the importance of long-term care, multidimensional assessment, and the latest data for biologics.
ADVENT at ERS 2024
The ADVENT program will present four symposia sharing the latest science in asthma and COPD at the 2024 European Respiratory Society (ERS) Congress. Visit Booth #A4.02 to learn more about ADVENT.
ADVENT at EADV 2024
Join ADVENT at EADV 2024 congress (European Academy of Dermatology and Venereology) for 2 educational symposia on type 2 inflammation in atopic dermatitis and bullous pemphigoid. Visit Booth #A13 to learn more about type 2 inflammatory skin diseases with ADVENT.
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis
The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.
What do we mean by disease control in AD?
Dr. Eric Simpson discusses the differing goals of patients and physicians in treating atopic dermatitis and emphasizes the importance of patient input.
Unlocking Better Outcomes: Strategies for Early Diagnosis and Effective Management in Pediatric EoE Patients
Pediatric gastroenterology experts Dr Carolina Gutiérrez Junquera and Dr Christos Tzivinikos where they discuss the importance of early identification and management of pediatric EoE to improve long-term outcomes. They highlight clinical data and discuss their practical experiences with pediatric EoE, including their perspectives on co-occurring type 2 inflammatory diseases, the chronic nature of EoE, and the future of EoE research and therapeutic development.
